XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.19.2

2. Acquisitions (Notes) | 6 Months Ended
--- | ---
Jun. 30, 2019
Business Combinations [Abstract] |
Business Combination Disclosure [Text Block] | ACQUISITIONS In March 2019, we completed the acquisition of all the issued and outstanding stock of a small private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. As of June 30, 2019, the preliminary allocation of the payments were $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles. The purchase price allocation is preliminary as additional time is required to complete the valuation of the intangibles. During the second quarter of 2019, we updated the valuation of the acquired assets by decreasing the amount of definite-lived intangibles by $6.5 million, and increasing goodwill and in-process research and development by $6.3 million and $0.2 million, respectively. In addition, we decreased deferred income tax liabilities and goodwill both by $1.4 million. We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration